Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Am J Gastroenterol. 2023 Nov 1;118(11):1989-1996. doi: 10.14309/ajg.0000000000002412. Epub 2023 Jul 19.
There is minimal evidence regarding the comparative effectiveness of individual antibiotics in the treatment of pouchitis. We sought to evaluate the comparative effectiveness of ciprofloxacin monotherapy, metronidazole monotherapy, and combination therapy (ciprofloxacin and metronidazole) in the treatment of an initial episode of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC).
We performed a retrospective cohort study in TriNetX, a global federated research network of electronic health records. Primary outcomes were failure of initial antibiotic therapy and the development of recurrent pouchitis in the first 12 months after an initial episode of pouchitis. One-to-one propensity score matching was performed for age, sex, race, primary sclerosing cholangitis, nicotine dependence, obesity, and previous exposure to tumor necrosis factor inhibitors between the cohorts.
Among 271 patients who developed pouchitis (mean age at ileal pouch-anal anastomosis 35.8 years, male sex 57%) and were treated with ciprofloxacin, metronidazole, or combination therapy, 190 (70%) developed recurrent pouchitis. After propensity score matching, there was no significant difference in the odds of early relapse or nonresponse with ciprofloxacin compared with metronidazole monotherapy (adjusted odds ratio 0.56, 95% confidence interval 0.23-1.34) or when either monotherapy was compared with combination therapy. There was also no significant difference in odds of recurrent pouchitis when comparing patients treated with ciprofloxacin with metronidazole monotherapy (adjusted odds ratio 0.86, 95% confidence interval 0.40-1.84) or either monotherapy with combination therapy.
In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis.
关于在治疗 pouchitis 方面,各种抗生素单独使用的相对疗效,相关证据很少。我们旨在评估环丙沙星单药治疗、甲硝唑单药治疗以及(环丙沙星+甲硝唑)联合治疗在溃疡性结肠炎行回肠贮袋肛门吻合术后初次 pouchitis 发作中的相对疗效。
我们在 TriNetX 中开展了一项回顾性队列研究,该研究是一个全球电子病历联合研究网络。主要结局为初始抗生素治疗失败和初次 pouchitis 发作后 12 个月内复发 pouchitis。采用年龄、性别、种族、原发性硬化性胆管炎、尼古丁依赖、肥胖和以前使用肿瘤坏死因子抑制剂等因素的 1:1 倾向评分匹配方法对队列进行匹配。
在 271 例出现 pouchitis(回肠贮袋肛门吻合术时的平均年龄为 35.8 岁,男性占 57%)并接受环丙沙星、甲硝唑或联合治疗的患者中,有 190 例(70%)发生了 pouchitis 复发。经倾向评分匹配后,与甲硝唑单药治疗相比,环丙沙星治疗早期复发或无应答的可能性并无显著差异(校正比值比 0.56,95%置信区间 0.23-1.34),或与联合治疗相比,两种单药治疗的可能性也无显著差异。与甲硝唑单药治疗相比,环丙沙星治疗的患者发生 pouchitis 复发的可能性也无显著差异(校正比值比 0.86,95%置信区间 0.40-1.84),或与联合治疗相比,两种单药治疗的可能性也无显著差异。
在这项回顾性队列研究中,我们未发现环丙沙星、甲硝唑或联合治疗在治疗初次 pouchitis 方面的实际疗效存在显著差异。